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Abstract
Lanthanide complexes are of increasing importance in cancer diagnosis and therapy, owing to the 
versatile chemical and magnetic properties of the lanthanide-ion 4f electronic configuration. 
Following the first implementation of gadolinium(III)-based contrast agents in magnetic resonance 
imaging in the 1980s, lanthanide-based small molecules and nanomaterials have been investigated 
as cytotoxic agents and inhibitors, in photodynamic therapy, radiation therapy, drug/gene delivery, 
biosensing, and bioimaging. As the potential utility of lanthanides in these areas continues to 
increase, this timely perspective of current applications will be useful to medicinal chemists and 
other investigators interested in the latest developments and trends in this emerging field.
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 1. Introduction
The problem of cancer is not new. It was recently reported that the oldest evidence of this 
disease was found in the remains of a 4,200 year old Egyptian woman.1 As cancer existed 
long before written history, it is no surprise that many different means of medical treatment 
have arisen. Some early treatments included the cauterization of tumors, and the ingestion of 
boiled barley mixed with nuts to treat stomach cancer.2 In 2015, the American Cancer 
Society estimated that about 1,600 people in the United States will die of cancer every day.3 
Owing to this epidemic threat, modern-day cancer diagnostic and therapeutic approaches 
have been evolving rapidly. In particular, a very powerful diagnostic method involves 
magnetic resonance imaging (MRI) in which metal-based contrast agents are administered to 
improve image resolution.
Chemotherapy, radiation therapy (XRT), and targeted therapy are some of the main types of 
cancer therapy. Chemotherapy involves drugs to kill cancer cells, while XRT uses high doses 
of radiation to eliminate tumors. Targeted therapy, as the name suggests, often uses small-
molecule drugs or monoclonal antibodies to target specific proteins that drive cancer cell 
proliferation. Small-molecule based drugs include inorganic compounds – most importantly 
the widely used cis-dichlorodiammineplatinum(II), better known as cisplatin. Indeed, metals 
are used extensively in cancer diagnosis and therapy, and the lanthanides occupy an 
important niche in these areas.
Lanthanides are elements with atomic numbers ranging from 57 (lanthanum) to 71 
(lutetium). They also are known as “rare earth” elements, because they were once thought to 
be present in very small amounts in the Earth's crust. However, we know today that 
lanthanides are relatively abundant. In 1803, the first lanthanide, cerium, was discovered in 
its mineral form – cerite.4 As lanthanides are extremely unstable when isolated in elemental 
form, they often are found as oxides and fluorides in rocks, ores, and minerals. As methods 
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for the extraction and separation of these lanthanides salts continue to improve, many 
investigators have turned their attention toward utilizing these elements in cancer imaging 
and therapy. The redox stability of Ln3+ ions makes them highly suitable for cellular 
applications in the presence of biological reducing agents like ascorbate and thiols, with the 
added advantage of favorable luminescent properties attributable to 4f↔5d, charge-transfer, 
and f↔f transitions.5 Currently, gadolinium-containing complexes – gadopentetic acid 
(Magnevist®) and gadoteric acid (Artirem®) – are commonly used as MRI contrast agents 
for cancer imaging,6 while lanthanide radioisotopes like 177Lu have been used in cancer 
imaging and therapy.7 Other forms of lanthanides, such as lanthanide oxide nanoparticles, 
nanodrums, and nanocrystals are promising as imaging agents and potential anticancer 
drugs.8 For example, CeO2 nanoparticles (Nanoceria) are used to inhibit the deleterious 
effects of reactive oxygen intermediates and are under development as potential therapeutic 
agents.9 However, the biomedical applications of lanthanides extend well beyond their use 
as routine cancer therapeutics and imaging agents, and publications detailing their use have 
increased over the last 10 years (Figure 1). Our Perspective highlights current work as well 
as insights that could drive future applications for this class of metals in cancer diagnosis 
and therapy – more specifically, we discuss recent developments in cytotoxic lanthanide 
agents and inhibitors, photodynamic therapy (PDT), XRT, drug/gene delivery, biosensing, 
and bioimaging. In addition, elements such as yttrium whose properties are similar to those 
of the lanthanides will be included throughout.
 2. Cytotoxic Agents and Inhibitors
One of the earliest applications of lanthanides in cancer therapy was reported by Anghileri 
and coworkers,10 who emphasized the importance of cationic cell membrane interactions in 
mediating Ln cytotoxicity. Following this work, other lanthanide-based anticancer agents 
were reported, with ones featuring complexation with a wide range of ligands, including 
hymecromone, umbelliferone, mendiaxon, warfarin, coumachlor and niffcoumar, 
coumarin-3-carboxylic acid, and dihalo-8-quinolinoline (Scheme 1: 2-Gd, 2-Sm, 2-Eu, 2-Tb, 
2-Dy, 3-Dy, 3-Er).11,12,13,14 Recently it was shown that oxoglaucine-lanthanide complexes 
(1-Y and 1-Dy) exhibited significantly greater cytotoxicity than the corresponding Ln(NO3)3 
salts.15 It was found that 2-Gd and 3-Dy interacted more strongly with DNA than the 
quinolinol ligand, with intercalation the most probable binding mode;12 and 1-Dy triggered 
DNA damage in hepatocellular carcinoma HepG2 cells, resulting in S phase cell cycle arrest 
and apoptosis.15 Most notably, 3-Dy (IC50: 18.3 ± 1.0 nm) and 3-Er (IC50: 31.5 ± 1.2 nm) 
are highly cytotoxic towards BEL-7404 human hepatocellular carcinoma cells, while both 
cisplatin (IC50: 132.8 ± 1.2 μM) and corresponding salts Dy(NO3)3 and Er(NO3)3 showed 
little to no cytotoxicity.12 Although the cytotoxic action of lanthanide complexes is typically 
attributed to their interactions with DNA, other mechanisms have been proposed: Pr3+, La3+, 
and Nd3+ were found to inhibit calcium transport in mitochondria (owing to similar ionic 
radii),16 and Yb-OEP-treated cells (Scheme 1) were found to undergo endoplasmic 
reticulum stress pathway-mediated apoptosis, with IC50 values in the sub-micromolar 
range.17 Other notable mechanisms include the inhibition of thioredoxin reductase18 and 
targeting of the glutathione-independent lipoate reduction pathway by gadolinium(III) 
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texaphryin (MGd, Xcytrin®) (Scheme 1),19 subsequently inhibiting cancer cell DNA 
replication, repair, and inducing oxidative stress.
In addition to small molecules, lanthanide nanomaterials (such as Nanoceria) are cytotoxic 
to several types of human cancer cells in vitro, including squamous cell carcinoma, 
hepatocellular carcinoma, alveolar epithelial cancer cells, and pancreatic carcinoma.20 These 
toxicities can be attributed to the induction of oxidative stress, the activation of mitogen-
activated protein-kinase (MAPK) signaling pathways, and the mimicking of superoxide 
dismutase, glutathione peroxidase, and catalase activities.20-21
A limitation associated with employment of the aforementioned lanthanide complexes and 
nanoparticles is selectivity – targeting cancer cells while leaving noncancerous cells 
unaffected. In order to overcome this problem, lanthanides are often conjugated to proteins 
or nucleic acids in order to confer specificity for more precise inhibition of proteins, and 
increased utility for imaging applications. Lanthanide-doped upconversion nanoparticles 
(UCNPs) can be conjugated to polo-like kinase 1 (Plk1)-specific peptides, enabling real-time 
imaging (980 nm excitation) while protecting these peptides from enzymatic degradation 
and inhibiting Plk1.22 Among the different NaGdF4@SiO2-Pn systems (spherical and cubic) 
investigated, spherical NaGdF4@SiO2-Pn inhibited HeLa cells selectively (IC50: 31.6 μg/ml) 
by causing G2 phase arrest while remaining nontoxic to normal cells.22 Other similar cell-
permeable systems include surface functionalized lanthanide nanoparticles UCNP-P1 
(Scheme 1) with cyclin D-specific peptides that inhibit the cyclin-dependent kinase 4 
(CDK4)/cyclin D complex,23 a promising anticancer target. As monoclonal antibody-drug 
conjugates such as trastuzumab emtansine and brentuximab vedotin have gained FDA 
approval,24 we expect that research in lanthanide antibody conjugates for therapeutic 
applications will experience rapid growth.
 3. Photodynamic Therapy
 a. UV-vis Photodynamic Therapy
Ultraviolet-visible (UV-vis) PDT is a promising modality for cancer treatment, owing to its 
precise tumor targeting ability. Upon UV-vis irradiation, a photosensitizer is initially excited 
to a singlet state that can undergo intersystem crossing (ISC) to a triplet state. The newly 
formed triplet state of the photosensitizer can react with molecular oxygen to generate 
singlet oxygen (1O2), a very powerful oxidant, which destroys malignant cells within its 
diffusion path. A singlet-oxygen generator, Photofrin®, a porphyrin-based drug that absorbs 
strongly in the Soret region, has been approved by the FDA for endobronchial and 
esophageal cancers. Lanthanide-based compounds also are very suitable for PDT as ISC is 
facilitated, owing to the heavy atom effect,25 which in turn promotes the generation of 
singlet oxygen. As a result, many lanthanide- substituted porphyrins and porphyrin analogs 
are potential PDT agents. The diamagnetic lutetium(III) texaphyrin (MLu, Lutrin®) 
(Scheme 1) localizes selectively in neoplastic tissues and generates singlet oxygen in 11% 
quantum yield in water.26 By irradiating at 732 nm (150 J cm−2 at 150 mW cm−2) at 3 h 
post-injection, 100% tumor ablation was observed in DBA/2N mice bearing fast-growing 
spontaneous mouse mammary tumor subline neoplasms of moderate size (70±35 mm3) with 
a dosage of 10 μmol kg−1. Other examples of lanthanide porphyrins include the water-
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soluble, mitochondria-permeable erbium(III) complex Er-L (Figure 2), which induced 
photocytotoxicity towards HeLa cells in vitro with modest formation of singlet oxygen (ΦΔ 
= 0.10),27 and gadolinium complexes Gd-N and Gd-RhB (Figure 3a) that effectively 
inhibited HeLa-tumors in BALB/c nude mice.28 Gd-N is an especially potent photosensitizer 
(51% singlet oxygen quantum yield) that specifically targets tumor cells via anionic 
phosphatidylserine membranes (Figures 3b-d), enabling the monitoring of laser-excited 
photoemission signals for live cancer cell tracking and imaging.
Lanthanide-doped nanoparticles are of intense interest, owing to long-lived luminescences, 
large antenna-generated Stokes or anti-Stokes shifts, narrow emission bands, high resistance 
to photobleaching, and low toxicity.29 In particular, lanthanide-doped UCNPs are promising 
photosensitizers for near-infrared (NIR)-triggered PDT. Aptly named, these UCNPs convert 
NIR light to visible light and offer remarkable light penetration depth without interference 
from auto-fluorescence in biological specimens under excitation.30 Recently, Wang and 
coworkers31 showed a large reduction in cell viability for MDA-MB-231 cells incubated 
with UCNP–ZnPc-COOH for 24 h and irradiated with a 980 nm NIR laser at 0.5 W cm−2 for 
10 min. In vivo PDT efficacy also was demonstrated in H22 tumor-bearing mice under 
similar NIR irradiation conditions 3 tumor volume in control mice increased from 248 to 
1282 mm3 after two weeks, whereas tumors in treated mice only increased from 240 to 501 
mm3 (Figures 4a,c) over the same period. Hematoxylin–eosin staining of tumor slices 
detected apoptotic and necrotic tumor cells, as shown in Figure 4d.
An unusual example of in vivo PDT illustrating the multi-functional modality of lanthanides 
was provided by treatment of U87MG tumor-bearing nude mice with chlorin e6 (Ce6)-
loaded UCNPs (UCNP-Ce6) followed by 980 nm irradiation (Figure 5).32 In addition to 
therapeutic tumor inhibition, these UCNPs also exhibited dual-modal imaging, as will be 
discussed below.
 b. X-ray Induced Photodynamic Therapy
X-ray excited optical luminescence of lanthanide-based nanoparticles is an attractive 
alternative to conventional light sources in traditional PDT due to the potential for deep 
tissue penetration.33 This unique therapy, first described by Chen and coworkers,34 relies on 
activation of scintillation nanoparticles by x-rays to produce optical emission that activates 
photosensitizers, which in turn produce cytotoxic ROS. Subsequently, many lanthanide-
based nanoparticles for x-ray induced PDT have been reported, including lanthanide-based 
micelles integrated with hypericin,35 as well as a porphyrin-conjugated Tb2O3 
nanoparticles.36 Energy transfer between the nanoscintillator and the porphyrin was 
demonstrated under UV excitation for the porphyrin-nanoparticle conjugate, while the yield 
of 1O2 increased with longer X-ray irradiation times.
 4. Radiation Therapy
As poor penetration of UV-vis light often has rendered PDT unsuitable for treating deep-
seated tumors, XRT (not to be confused with x-ray induced PDT) has gained popularity in 
recent years due to the potential for deep tissue targeting of tumors without the requirement 
for photosensitizers. After release from atoms irradiated with x-rays, inner shell electrons 
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react with water and oxygen, generating free radicals and causing tissue damage via 
secondary reactions.37 Over the past few decades, many methods of using lanthanides in 
several types of XRT – brachytherapy, external beam radiotherapy, systemic radioisotope 
therapy with unsealed radiation sources – have been developed. In radioimmunotherapy, 
a 177Lu–labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 
J591, induced a measurable response rate in metastatic castration-resistant prostate cancer in 
a Phase II clinical trial (Figure 6).38
One of the first lanthanide-based metal-ligand complexes considered for XRT was MGd, 
which kills malignant cells via endocytosis by a clathrin-dependent pathway and subsequent 
induction of apoptosis.39 However, the efficacy of MGd as a general radiosensitizing agent 
is still debatable as it did not inhibit potentially lethal damage repair (repair of double-
stranded breaks) in murine breast cancer EMT6 cells40 and negative radiosensitivity results 
were obtained in two tumor models.41 Yttrium, a rare-earth element that is congeneric with 
lanthanides, has been incorporated into ibritumomab tiuxetan (Zevalin) – an FDA-approved 
drug that has been effective in treating B-cell non-Hodgkin's lymphoma.42 By attaching the 
murine anti-CD20 antibody ibritumomab to β−-emitting 90Y via the linker-chelator tiuxeton, 
radiation can be selectively deposited in CD20+ cells.43 This use of antibodies for targeted 
XRT is otherwise known as radioimmunotherapy (RIT).
More recently, lanthanide-based nanoparticles have been investigated as RIT agents. 
Typically, these radiosensitizing nanoparticles are composed of a core, a shell, and a surface. 
The core is made of elements like lanthanides for increased photon absorption. The shell 
acts as a base on which surface molecules are attached; and it also can confer additional 
properties such as the retention of radioactive daughter elements after decay. The surface 
molecules confer selectivity to the nanoparticles through the anchoring of site-, tissue-, cell- 
and/or receptor-specific molecules. One such example is a gold-coated lanthanide phosphate 
nanoparticle ({La0.5Gd0.5}PO4@GdPO4@Au) containing the therapeutic 
radionuclide 225Ac that can act as an in vivo α-emitter, which is an advantage over β− 
emitters due to their shorter range of emission (50–100 μm) along with high linear energy 
transfer.44 Additionally, effective cell killing can be expected in hypoxic tumors since 
cytotoxicity is oxygen independent. These advantages could provide the impetus for further 
development of ‘α-radioimmunotherapeutics’.
 5. Drug/Gene Delivery
Owing to the very high charge to volume ratios of tripositive lanthanides, which facilitate the 
formation of Ln3+-adenovirus complexes, several Ln cations were investigated for their 
ability to enhance transduction efficiency of adenovirus vectors in vitro and in vivo.45 La3+ 
was found to be superior to Gd3+, Y3+, Lu3+, and even Ca2+. Lanthanide oxide 
nanostructures are promising drug delivery materials due to their ease of synthesis and 
exceptionally low dimensionality. Sm2O3 and Gd2O3 ultrathin nanosheets46 were found to 
exhibit promising pH-controlled anticancer drug-delivery properties (Figure 7). 
Interestingly, fast 5-fluorouracil release was found at pH 4.0 relative to pH 7.4. The fast 
release behavior was attributed to the alkaline nature of nanosheets, which makes them 
highly attractive due to the acidic environment of tumor cells.
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Several lanthanide-doped nanomaterials, in particular UCNPs, act as drug and gene delivery 
systems.47 These UCNPs are popular since they can be used as image-guided therapy (IGT) 
agents – see discussions in later sections of this Perspective. However, there are still many 
possibilities to be explored in the field of drug/gene delivery. The incorporation of 
lanthanides in smart polymers that respond to chemical and physical stimuli for controlled 
delivery could lead to new therapeutic approaches.
 6. Biosensing
Lanthanides are components in many biosensors: both emission-based and mass 
spectrometry (MS)-based bioassays have been extensively employed.
 a. Emission-based Bioassays
Emission-based bioassays rely on fluorescence/luminescence for detection. They can be 
broadly divided into two categories – heterogeneous and homogeneous bioassays. 
Heterogeneous assays feature high affinity binding to target analytes through the use of 
capture molecules immobilized on a solid substrate. Notably, Ln3+-doped UCNPs have been 
investigated for the detection of analytes due to the elimination of interference from 
background autofluorescence of biological cells and tissues.33 Photostable single-band 
UCNPs (sb-UCNPs) were used to determine the expression levels of three biomarkers 
(estrogen receptors, progesterone receptors and human epithelial growth factor receptor-2) in 
breast cancer cells and tissue specimens via photoluminescence (PL), western blotting, 
immunocytochemistry (ICC), and immunohistochemistry (IHC).48 Excellent correlations 
between sb-UCNP molecular profiling technology and ICC/IHC for protein expression in 
cell lines and biopsies (Figures 8a-b) were demonstrated, indicating that this new technology 
is a promising alternative for the multiplexed quantification of multiple tumor biomarkers. 
Other reports using Ln3+-doped nanoparticles as bioprobes include the detection of 
additional tumor biomarkers such as urokinase plasminogen activator receptor, 
carcinoembryonic antigen; the recognition of a mucin-like protein expressed on human 
breast cancer MCF-7 cells by lanthanide binuclear helicate-avidin conjugates, and the 
detection of lysophosphatidic acid (a biomarker for ovarian cancer and other gynecologic 
cancers) by a methanol suspension of a Tb3+ and Eu3+ mixed-crystal metal-organic 
framework.49,50,51,52
In contrast to heterogeneous bioassays, homogeneous bioassays are largely based on the 
principles of Förster resonance energy transfer (FRET) for detection of protein-protein 
interactions, where long-range dipole–dipole interactions facilitate energy transfer between 
an excited donor molecule on one protein and a nearby acceptor molecule on another 
protein. Because of the suitability of lanthanide nanoparticles as FRET donors, including the 
inherently large Stokes shift of lanthanide systems that allows excitation at much shorter 
wavelengths than acceptor absorptions,53 these nanoparticles have found their way into 
many homogeneous assays. Wang and coworkers54 have designed a novel upconversion 
phosphor (UCP)-FRET biosensor for the detection of a cancer biomarker, matrix 
metalloproteinase-2, by using polyethylenimine-modified NaYF4:Yb/Er UCPs and carbon 
nanoparticles as donor-acceptor pairs.
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Many emission-based assays highlighted in this section also can be employed as time-
resolved (TR) luminescent-based assays. Upon pulsed excitation of the lanthanide labels in 
lanthanide chelates and lanthanide-doped nanocrystals, the long-lived PL signal within an 
appropriate gate time is retained while the short-lived background noise is impeded within 
the delay time.55 Due to high signal-to-noise ratios and detection sensitivities, TR 
fluoroimmunoassays using Ln3+-chelates have been commercialized.56 Heterogeneous 
TRPL assays and homogeneous TR-FRET assays also have been used to detect a variety of 
biomarkers and biomolecules, including the soluble urokinase plasminogen activator 
receptor with an impressive limit of detection of ~328 pM (similar to that found in the serum 
levels of cancer patients).56-57 Several comprehensive reviews are available that cover this 
important area.55,58,59,60
 b. Mass Spectrometry-based Bioassays
A combination of lanthanide labels and MS techniques has been used to detect a wide 
variety of nucleic acid and protein cancer biomarkers. Methods to multiplex proteins in 
FFPE tumor tissues using antibodies labeled with isotopic lanthanides and detection using 
secondary ion mass spectrometry have been developed.61 Inductively coupled plasma MS 
(ICP-MS)-based analysis of lanthanide-labeled compounds has several advantages: (1) 
greater signal to noise due to the negligible natural biological abundance of lanthanides; (2) 
polyatomic interferences are rarely significant; (3) high ionization efficiency due to low first 
ionization potentials; (4) similar chemical properties suitable for multiplexed assays based 
on ICP-MS, and (5) potential for quantification using isotope dilution.62 In a comprehensive 
review by de Bang and coworkers, applications of lanthanide-labeled proteins, nucleic acids, 
and ICP-MS in immunoassays and hybridization assays were covered in detail.62
Although methods for nucleic-acid detection using lanthanide labeled probes are still in their 
infancy, there have been steady developments in this area over recent years. One recent 
example demonstrated the detection of Arabidopsis thaliana microRNAs (miRNAs) on 
Northern blot membranes by laser ablation inductively coupled plasma mass spectrometry 
using 165Ho, 159Tb, and 169Tm-labeled complementary DNA probes (Figure 9).63 Following 
this proof-of-concept, it would be of interest to investigate the use of such probes to detect 
miRNA biomarkers and circulating tumor DNA for early cancer diagnosis.
 c. Drug Design
It is well established that molecular interactions in solution can be followed by nuclear 
magnetic resonance (NMR) spectroscopy. In work exploiting NMR, a Dy3+ or Tm3+-
conjugated carbohydrate ligand was used to observe binding to the human galectin-3 
carbohydrate recognition domain via pseudocontact shifts arising from the transfer of 
paramagnetic lanthanide signals to protein nuclei.64 This method has potential applications 
for screening ligand-protein interactions, finding target sites for cancer drug discovery, and 
aiding in drug design.
Lanthanide ions, including Lu3+ and Tb3+, also have been employed for protein crystal 
structure determination.65,66 Two Tb3+-binding modules connected to a 32-residue peptide 
tagged to ubiquitin were used for accurate structure determination by a single-wavelength 
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anomalous diffraction method, thereby eliminating the need for unnatural amino acids or 
some other chemical modification of the protein (Figure 10).65 Tagging proteins with fusion 
peptides helps solve the phase problem, owing to robust anomalous signals from Ln ions, 
thereby offering structural biologists another powerful method for the determination of 
cancer-implicated protein structures required for inhibitor design.
 7. Bioimaging
Lanthanides have been extensively employed as bioimaging agents for cancer diagnosis and 
treatment. In this section, lanthanides for MRI, NIR emission imaging, dual-/multi-mode 
imaging, IGT, and time-resolved luminescence imaging will be discussed briefly. For more 
in depth coverage, reviews on bioimaging applications using lanthanide nanoparticles are 
recommended.29, 67
 a. Magnetic Resonance Imaging
Among the lanthanide ions, Gd3+ is especially suitable as a contrast agent, owing to its 
paramagnetism (with seven unpaired 4f electrons) and long electronic relaxation time. It is 
an ideal lanthanide ion for longitudinal T1 relaxation enhancement. As uncomplexed Gd3+ is 
cytotoxic, it is normally used in chelated form (two examples are the well-known 
gadopentetic acid and gadoteric acid or encapsulated in nanomaterials, including 
nanocrystals, nanoparticles, and carbon nanostructures).68 Other lanthanide ions such as 
Eu3+, Dy3+, and Er3+ that possess asymmetric electronic ground states, strong magnetic 
anisotropy, short electronic relaxation times, and large magnetic moments have been 
investigated as nanoparticle--based contrast agents in T2-weighted MRI.29,69
 b. Near-infrared Excitation-based Imaging
UCNPs can combine two or more lower energy photons to generate a single high-energy 
photon by an anti-Stokes process.70 As a result, lanthanide-doped UCNPs have been 
extensively investigated in recent years as NIR imaging agents due to their excellent 
photostability, continuous emission capability, sharp multi-peak line emission, and long 
luminescence decay times (much longer than those of organic dyes and quantum dots).70 In 
addition, light scattering by biological tissues is substantially reduced with NIR excitation, 
resulting in greater penetration depth than possible with UV-vis excitation. One example is 
the in vivo luminescence imaging of tumors by hexagonal phase NaYF4:Yb,Er/NaGdF4 
core-shell UCNPs conjugated with Ce6 as contrast agents (Figure 11).32
 c. Dual-/Multi-mode Imaging
Dual-/multi-mode imaging is becoming increasingly attractive as it combines the advantages 
of penetration depth, resolution, and sensitivity of different modalities, thereby providing 
more information than can be obtained from a single technique. Most reports of dual-/multi-
modal imaging describe the application of lanthanide nanomaterials rather than lanthanide 
complexes due to their greater versatility and ease of preparation. The most common 
nanomaterials reported are, unexpectedly, lanthanide-doped UCNPs, which have found their 
way into a myriad of imaging modalities, including dual T2-weighted MRI and upconversion 
luminescence imaging,71 and in vivo four-modal imaging (upconversion luminescence 
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imaging, X-ray computed tomography, MRI, and single-photon emission computed 
tomography).72
 d. Image-guided Therapy
As noted in previous sections (PDT, XRT, and drug/gene delivery), the incorporation of 
lanthanides into nanosystems and complexes serves a key purpose for IGT. IGT is important 
for the accurate determination of location and treatment of tumor sites. Specifically, 
lanthanide-doped UCNPs convert NIR excitation energy into UV-vis luminescence used to 
photorelease drugs and monitor their delivery. Previously reported applications include the 
photoisomerization driven release of doxorubicin73 – as NaYF4:TmYb@NaYF4 UCNPs 
emit photons in the UV-vis region upon irradiation by NIR light, the azo moieties in the 
silica layer interconvert reversibly between cis and trans conformations (Figure 12a) and act 
as molecular impellers driving the release of encapsulated doxorubicin from silica 
mesopores (Figure 12b).
 e. Time-resolved Luminescence Imaging
This imaging technique involves time-resolved luminescence microscopy (TRLM) and Ln3+ 
tags for cancer cell imaging.74 TRLM is able to eliminate short-lifetime (< 100 ns) 
autofluorescence background from biological specimens and overcome the low photon 
emission from lanthanide probes by employing light-emitting diodes for pulsed epi-
illumination and intensified charge-coupled device cameras for gated, widefield detection.75 
For example, self-assembled Eu3+ bimetallic helicates (Eu2(LC5)3) were found to localize 
into endosomes and/or lysosomes of HeLa cells by a combination of bright-field microscopy 
and TRLM (Figure 13).76
The development of new technologies and lanthanide tags for TRLM is advancing rapidly;77 
in this area, recent investigations employing time-resolved confocal microscopy78 and time-
resolved orthogonal scanning automated microscopy are of wide interest.79
 8. Concluding Remarks and Future Outlook
As the worldwide incidence of cancer continues to rise, the discovery and continual 
refinement of diagnostics and therapeutics remain ongoing challenges. Increased 
availabilities of lanthanide compounds with outstanding stability (photo- and redox-stability) 
and luminescent properties have led to myriad applications in cancer therapy and imaging – 
as cytotoxic agents, inhibitors; in PDT, XRT, drug/gene delivery, biosensing, and 
bioimaging. Together with the utilization of lanthanide-based conjugates of biopolymers, it 
is likely that multi-modal IGT will be an attractive approach, as drugs can be released on 
demand via environmental stimuli and uptake can be accurately monitored, allowing for 
great specificity in tumor targeting.
Immunotherapeutics often have been heralded as the future of cancer medicine.80 Therefore, 
another key area of development involves nanoparticle-based strategies that incorporate 
immune potentiators and α-emitters as a new-generation of lanthanide-based RIT agents. 
Immune potentiators function as vaccine adjuvants while α-emitters, as previously 
discussed, leave healthy cells unaffected by radiation.
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Lastly, owing to the recently discovered potential of adoptive cell transfer in treating a wide 
variety of cancers,81 lanthanide-based labeling of chimeric antigen receptor T-cells for real-
time biotracking and bioimaging is a promising avenue for exploration, as there is great 
therapeutic potential in this area.
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FRET Förster resonance energy transfer
ICP-MS inductively coupled plasma mass spectrometry
IGT image-guided therapy
ICC immunocytochemistry
IHC immunohistochemistry
ISC intersystem crossing
MAPK mitogen-activated protein kinases
miRNA micro-ribonucleic acid
MRI magnetic resonance imaging
MS mass-spectrometry
NIR near-infrared
NMR nuclear magnetic resonance
PDT photodynamic therapy
PL photoluminescence
Plk1 polo-like kinase 1
PMSA prostate-specific membrane antigen
RIT radioimmunotherapy
RNA ribonucleic acid
ROS reactive oxygen species
sb-UCNP single-band upconversion nanoparticle
TR time-resolved
TRLM time-resolved luminescence microscopy
UCNP upconversion nanoparticle
UCP upconversion phosphor
UV ultraviolet
UV-vis ultraviolet-visible
XRT radiation therapy
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Figure 1. 
Number of articles in Web of Science on the topic “lanthanide” and “cancer” from 2005 to 
2015.
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Scheme 1. 
Structures of lanthanide-based molecules and nanoparticles that function as cytotoxic agents 
and inhibitors.
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Figure 2. 
Molecular structures of porphyrin-based lanthanide complexes, Er-L and Yb-L (Yb-L served 
as the control). Reproduced from ref. 27 with permission of the Royal Society of Chemistry.
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Figure 3. 
a) Structure of “smart” cancer cell-specific PDT agent (Gd-N) and control analogs Yb-N and 
Gd-RhB. b) 3D in vitro imaging of Gd-N after 15-h incubation in HeLa cells. Subcellular 
localization of Gd-N in c) cancer cells (HeLa) and d) normal cells (WPMY-1). Reproduced 
with permission from ref. 28 (© 2014 National Academy of Sciences, USA).
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Figure 4. 
Variation of (a) tumor volumes and (b) body weights of mice in experimental and control 
groups, respectively. Each data point represents the average value of 5 mice. (c) 
Representative photos of a mouse showing tumors at 14 days after treatment in experimental 
and control groups, respectively. (d) Images (left) and the corresponding high-resolution 
images (right) of hematoxylin–eosin stained tumor tissues harvested from the experimental 
and control groups after 14 days. Reproduced from ref. 31 with permission of the Royal 
Society of Chemistry.
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Figure 5. 
Schematic of dual-modal imaging and PDT using UCNP–Ce6. Reproduced with permission 
from ref. 32 (© 2012 John Wiley & Sons Inc.).
Teo et al. Page 23
J Med Chem. Author manuscript; available in PMC 2017 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Left panels: Anterior (A) and posterior (B) 99mTc-MDP bone scan images of pre- treatment 
bony metastases. Right panels: Anterior (C) and posterior (D) total body images obtained 
(via dual head gamma camera) of sites of uptake 7 days after 177Lu-J591 administration. 
Note 177Lu-J591 is cleared via the liver. Reproduced with permission from ref. 38 (© 2010 
John Wiley & Sons Inc.).
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Figure 7. 
Formation pathway for Sm2O3 and Gd2O3 nanostructures, as well as pH-controlled 
anticancer drug delivery. Reproduced with permission from ref. 46 (© 2015 John Wiley & 
Sons Inc.).
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Figure 8. 
Comparative statistical analysis of multiplexed detection with sb-UCNPs and IHC. (a) using 
two breast cancer cell-lines: MCF-7 and MDA-MB-231 (b) using three formaldehyde fixed-
paraffin embedded (FFPE) human breast cancer tissues with primary antibodies-conjugated 
sb-UCNPs. Scale bar, 20 μm. Reproduced with permission from ref. 48 (© 2015 Nature 
Publishing Group).
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Figure 9. 
miRNAs were northern blotted and incubated with lanthanide-labeled DNA probes. After 
hybridization and washing, the membrane was analyzed by laser ablation inductively 
coupled plasma mass spectrometry. The dry aerosol created by laser ablation was introduced 
to the ICP-MS for online detection of the lanthanide composition, thereby enabling 
multiplex detection of miRNAs.63
Teo et al. Page 27
J Med Chem. Author manuscript; available in PMC 2017 July 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 10. 
Structure of a seven-coordinate lanthanide-peptide tagged to ubiquitin (PDB accession code 
2OJR). Color coding: Tb3+ (pink spheres), N (blue), O (red), C (cyan).
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Figure 11. 
a,b) Upconversion luminescence images of nude mice after 1.5 h intravenous injection a) 
without and b) with UCNPs. Left are bright field images, middle are red luminescence 
images, and right are green luminescence images. c,d) Upconversion luminescence images 
of nude mice bearing tumors after intravenous injection of c) UCNPs and d) UCNP-Ce6. 
Arrows indicate tumor sites. Top row, bright field images, middle row, true-color images of 
green luminescence, and bottom row, pseudo-color images converted from the 
corresponding true-color images (middle row) using ImageJ image analysis software (http://
rsb.info.nih.gov/ij/). Red luminescence was recorded using a red band pass filter (641.5 
− 708.5 nm, Semrock), and green luminescence was recorded using a combination of a 
green band pass filter (517 − 567 nm, Semrock) and an 850 nm short pass filter (SPF-850, 
CVI). Reproduced with permission from ref. 32 (© 2012 John Wiley & Sons Inc.).
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Figure 12. 
a) Procedure for the synthesis of upconverting nanoparticles coated with a mesoporous silica 
outer layer. b) NIR light-triggered doxorubicin release by making use of the upconversion 
property of UCNPs and trans–cis photoisomerization of azo molecules grafted in the 
mesopore network of a mesoporous silica layer. Reproduced with permission from ref. 73 
(© 2013 John Wiley & Sons Inc.).
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Figure 13. 
Merged bright-field and time-resolved luminescence microscopy of HeLa cells loaded with 
[Eu2(LC5)3]. Top row: Cells incubated with various concentrations of [Eu2(LC5)3] in 
RPMI-1640 for 6 h at 37 °C; conditions: Pan-Fluor lens 40× magnification, 365 nm 
excitation (BP 80 nm), 420 nm LP emission filter, 100 μs delay, 30 s exposure time. Bottom 
row: Time-course of the uptake upon incubation at 37 °C with [Eu2(LC5)3] 200 μM; same 
conditions as above, but for magnification (100×) and excitation (340 nm, BP 70 nm). 
Reproduced with permission from ref. 76 (© 2009 John Wiley & Sons Inc.).
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